Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.
about
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapiesCombination of celecoxib and PD184161 exerts synergistic inhibitory effects on gallbladder cancer cell proliferation.Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinomaEGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinomaMolecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract CancerMolecular characterization of gallbladder cancer using somatic mutation profiling.BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer.Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer.Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinomaIdentification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma.Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in miceGenomic Alterations in Biliary Tract Cancer Using Targeted Sequencing.Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells.The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.Gallbladder cancer: can newer insights improve the outcome?Chemotherapy for the biliary tract cancers: moving toward improved survival time.Potential biomarkers in gallbladder cancer: present status and future directions.Prognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis.Immunotherapy of biliary tract cancer.Secreted cyclophilin A mediates G1/S phase transition of cholangiocarcinoma cells via CD147/ERK1/2 pathway.Down-regulation of FoxM1 inhibits viability and invasion of gallbladder carcinoma cells, partially dependent on inducement of cellular senescencePlatelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma.Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies.Prognostic impact of tumoral and/or peri-tumoral stromal SPARC expressions after surgery in patients with biliary tract cancer.Immunohistochemical study of PUMA, c-Myb and p53 expression in the benign and malignant lesions of gallbladder and their clinicopathological significances.Platelet-derived growth factor D: a new player in the complex cross-talk between cholangiocarcinoma cells and cancer-associated fibroblasts.Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma.Downregulation of PIM1 regulates glycolysis and suppresses tumor progression in gallbladder cancer
P2860
Q27002547-95DE925A-F523-4924-BEEF-38E2F50971FDQ33684263-608ACADC-523E-4CE0-9DF6-9E3371A7AF17Q33757003-92050023-8C44-479E-BFDB-B1DBC347366CQ34738001-F42ECE00-A077-4D8C-BB9E-A8A08C48F254Q35150642-639548BA-D174-4382-B29C-865C420024C0Q35597012-E2B2C5F7-76B3-4707-BD70-6F88A13AABB5Q35674192-1861199E-D2F6-4DD3-84C5-85EBDC9F8561Q35696749-6101F069-571B-4E47-8DDE-ADA36E3B1955Q35705307-17594797-40FA-4590-90CB-E9FD3F81C30CQ35840582-9CF58894-3422-480A-88BF-23EA3997CDEAQ36414244-A54F516B-3356-4516-ACF7-E0F9ECD8287AQ36544718-FC9A670C-7B56-4EE7-B026-0E3A4810A05FQ36870198-F41C10E8-7967-49E7-B963-7122C44FF0D9Q37709171-248BE7AA-A313-4808-8356-00A5E7ECEBD5Q37964960-582A9C7C-B731-4582-8904-93B9B460EE19Q37968331-943FE8A6-E178-4175-A8A2-C5FDA81EFC4BQ37983498-591D6BA1-8414-498E-B24C-6FED458F35DCQ38038882-5EBEEEB4-B816-40B7-BBF4-3BF090E7278FQ38148062-F567C636-4B82-4D5E-A434-5939CAADDD39Q38686339-8F277C96-DFA6-4FF8-AEF2-EF0480875F8DQ38949695-F9646005-6355-4363-9500-8BD7098FCFD7Q38970720-3EB0C578-C128-4F46-A9E7-0C443D95D357Q39179249-EC4463DC-CCD6-4CDD-A6B3-E5EDD92E88D8Q39312152-0F929ADF-7FDC-4BBE-9F11-288F6E8DFAEDQ42272472-D9CC0671-7F7F-4C15-AEC7-67DBA508D190Q43646189-DF975AC7-B345-406A-8E25-2371A6A28AD5Q50173842-FBC69954-86CC-4421-84D6-3F1BF4254214Q50972322-E9F63260-2B91-4168-AFE9-16297B900C06Q55497250-E67AC26F-33B8-4CA7-9869-DEA15C7B1B05Q59126036-36D0FAB8-B10F-4CD4-81E6-344F519A723F
P2860
Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of molecularly tar ...... challenges and opportunities.
@en
Development of molecularly tar ...... challenges and opportunities.
@nl
type
label
Development of molecularly tar ...... challenges and opportunities.
@en
Development of molecularly tar ...... challenges and opportunities.
@nl
prefLabel
Development of molecularly tar ...... challenges and opportunities.
@en
Development of molecularly tar ...... challenges and opportunities.
@nl
P2860
P356
P1433
P1476
Development of molecularly tar ...... challenges and opportunities.
@en
P2093
Andrew X Zhu
Aram F Hezel
P2860
P304
P356
10.1002/HEP.24145
P407
P577
2011-02-01T00:00:00Z